Sulfur Nonionically Bonded Patents (Class 514/562)
-
Patent number: 8715632Abstract: Compositions for treating hair are disclosed. Methods of making and using compositions for treating hair are also disclosed.Type: GrantFiled: November 26, 2012Date of Patent: May 6, 2014Inventor: S. Katharine Presty
-
Publication number: 20140121237Abstract: The present invention provides methods for treating a subject having, or at risk of having, a viral infection. The methods include, but are not limited to, the use of 4-(dipropylsulfamoyl)benzoic acid, an inhibitor of CDC25B phosphatase, an inhibitor of ICAM-1, an inhibitor of CamK2B, or a combination thereof.Type: ApplicationFiled: October 14, 2013Publication date: May 1, 2014Inventors: RALPH A. TRIPP, STEPHEN M. TOMPKINS
-
Publication number: 20140121269Abstract: Systems, techniques and methods for estimating the metabolic state or flux, e.g., the body energy state (“BES”) of a patient, are disclosed. The BES provides deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis, which is the % of glucose production that comes from gluconeogenesis (“GNG”), as opposed to glycogenolysis (“GLY”), the other form of glucose production. Nutritional formulations, materials, cocktails and methods for feeding patients by parenteral and other means are disclosed. The amount, type and rate of such nutritional feeding are typically based upon the above estimating. The invention discloses formulations that contain labels, such as deuterium, for medical diagnostics, such as for estimating BES and fractional gluconeogenesis.Type: ApplicationFiled: May 28, 2013Publication date: May 1, 2014Applicant: Run Them Sweet, LLCInventors: Michael A. Horning, George A. Brooks
-
Publication number: 20140121277Abstract: Methods for treating or preventing an inflammatory response comprising administering an enantiomer or racemic mixture of methionine sulfoximine (MSO). The MSO may be L-methionine S-sulfoximine (LSMSO), L-methionine R-sulfoximine (LRMSO), or racemic mixture of LSMSO and LRMSO. Methods include those for treating liver failure associated with an inflammatory response.Type: ApplicationFiled: September 9, 2013Publication date: May 1, 2014Inventors: William Brusilow, Paolo Bernardi
-
Publication number: 20140113969Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the hType: ApplicationFiled: September 18, 2013Publication date: April 24, 2014Applicant: PHILERA NEW ZEALAND LIMITEDInventors: Garth J.S. Cooper, John R. Baker
-
Publication number: 20140107027Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: BHI LIMITED PARTNERSHIPInventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
-
Publication number: 20140100183Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.Type: ApplicationFiled: April 12, 2013Publication date: April 10, 2014Applicant: The Regents of the University of Colorado, a body corporateInventors: Daniel J. ABRAMS, Raymond BUNCH, Tom ANCHORDOQUY, Karen E. STEVENS
-
Publication number: 20140100283Abstract: An improved method for delivery of glutathione, a major intracellular antioxidant, by oral administration of S-acetyl-glutathione (SAG) is provided. The method is designed to raise the circulating blood levels of glutathione via the administration of an effective amount of SAG in a delayed release composition.Type: ApplicationFiled: October 7, 2013Publication date: April 10, 2014Applicant: Atlantic Pro Nutrients, Inc. dba XYMOGENInventor: Mike Mahoney
-
Publication number: 20140094466Abstract: In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment compositions of the invention slow or inhibit F-actin depolymerization and severing. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit cell motility and/or internal remodeling. In alternative embodiments, compositions and methods of the invention are used to slow or inhibit, or reverse, or ameliorate the progression of a cancer or a metastasis or other uncontrolled or unregulated cell growth, and/or Alzheimer's disease.Type: ApplicationFiled: March 15, 2012Publication date: April 3, 2014Inventors: Jason H. Haga, Shu Chien, Matt Mui, Marshall J. Levesque, Phillip D. Pham
-
Publication number: 20140094455Abstract: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.Type: ApplicationFiled: August 19, 2013Publication date: April 3, 2014Applicant: ARIZONA BOARD OF REAGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Gary A. Flynn, Andrea J. Yool, Elton Rodrigues Migliati, Leslie S. Ritter
-
Patent number: 8686167Abstract: Activated fatty acids, pharmaceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.Type: GrantFiled: October 1, 2010Date of Patent: April 1, 2014Assignee: Complexa, Inc.Inventor: Raymond A. Miller
-
Publication number: 20140079812Abstract: Compositions and methods for the treatment of cancer are provided.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: Lankenau Institute for Medical ResearchInventors: Iraimoudi S. Ayene, George C. Prendergast
-
Publication number: 20140080910Abstract: The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons for use in the treatment of autism in a baby or a fetus in need thereof.Type: ApplicationFiled: November 22, 2013Publication date: March 20, 2014Applicant: NEUROCHLOREInventors: Yehezkel BEN-ARI, Diana Carolina FERRARI, Romain NARDOU
-
Patent number: 8673964Abstract: The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and/or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with pharmaceutical compositions described herein. The invention also provides for a kit comprising a pharmaceutical composition and instructions for its use.Type: GrantFiled: May 20, 2005Date of Patent: March 18, 2014Assignee: DiaMedica Inc.Inventor: Wilfred Wayne Lautt
-
Publication number: 20140073611Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.Type: ApplicationFiled: May 21, 2013Publication date: March 13, 2014Applicant: National Taiwan UniversityInventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
-
Publication number: 20140073694Abstract: The present invention relates to the use of cystamine analogues for the treatment of Parkinson's disease. The present invention also relates to the use of composition comprising cystamine analogues and cysteine. The present invention relates to a method for modifying the progression of Parkinson's disease comprising administering a therapeutically effective amount of at least one cystamine analogue or a pharmaceutically acceptable salt of a cystamine analogue to a patient in need thereof.Type: ApplicationFiled: February 23, 2012Publication date: March 13, 2014Applicant: UNIVERSITE LAVALInventors: Francesca Cicchetti, Claude Rouillard, Frederic Calon
-
Patent number: 8664269Abstract: Those in need of nitroglycerin (GTN) therapy who have polymorphism in the mtALDH gene, e.g., those of Asian descent for whom this polymorphism is common, and/or who are being treated with or ingesting or exposed to mtALDH inhibitor are treated with GTN in combination with agent which converts GTN to product which is metabolized without mtALDH activity, e.g., N-acetylcysteine.Type: GrantFiled: November 8, 2006Date of Patent: March 4, 2014Assignee: Duke UniversityInventors: Jonathan S. Stamler, Gregory T. Went
-
Patent number: 8664272Abstract: Methods and compositions are provided for treating myelodysplastic syndrome and acute myeloid leukemia, wherein the composition comprises at least one compound according to Formula I: wherein R1 is selected from the group consisting of —NH2, —NH—CH2—CO2H, —NH—CH(CH3)—CO2H, and —NH—C(CH3)2—CO2H, or a pharmaceutically acceptable salt of such a compound; and a DNA methyltransferase inhibitor, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 30, 2006Date of Patent: March 4, 2014Assignees: Temple University—Of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount SinaiInventors: E. Premkumar Reddy, M. V. Ramana Reddy, James F. Holland, Lewis R. Silverman, Svetlana Zinzar
-
Publication number: 20140050677Abstract: Personal care products useful for the maintenance of personal appearance and good health and minor treatments that do not require professional health care, as well as products that provide a combination of anti-oxidant, anti-inflammatory, antimicrobial, and anti-aging properties and are suitable for use without a prescription. The products utilize biomembrane permeable organosulfur compounds that can redox cycle between thiol, disulfide, and thiosulfinate forms in response to antioxidants and oxidants that are inside and outside of cells. Example products include an antioxidant skin lotion with anti-inflammatory, antimicrobial, anti-arsenicosis, anti-aging, and deodorant properties.Type: ApplicationFiled: October 19, 2013Publication date: February 20, 2014Inventor: David Michael Ott
-
Publication number: 20140045937Abstract: The invention provides a method of treating or preventing polycystic ovarian syndrome (PCOS) in a mammal, comprising administering chlorogenic acid in an amount effective to treat or prevent PCOS in the mammal. In an embodiment of the invention, the method further comprises administering L-cysteine to the mammal.Type: ApplicationFiled: August 7, 2013Publication date: February 13, 2014Inventor: James J. Schutz
-
Publication number: 20140044797Abstract: The present invention relates to the novel use of prostacyclin analogs for prevention and/or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment.Type: ApplicationFiled: March 30, 2012Publication date: February 13, 2014Applicant: RigshospitaletInventors: Par Johansson, Sisse Rye Ostrowski
-
Publication number: 20140039055Abstract: Topical compositions to address menopausal skin conditions include an effective amount of S-acyl glutathione derivative and a carrier. Methods for addressing menopausal skin conditions include applying a composition containing S-acyl glutathione derivative in a dermatologically acceptable carrier to skin tissue. The acyl group is a saturated or unsaturated aliphatic C12-C24 group, preferably an unsaturated C16-C24 group, most preferably an unsaturated C18 group. In particularly preferred embodiments, the acyl group is a linoleoyl group.Type: ApplicationFiled: October 10, 2013Publication date: February 6, 2014Inventor: Nicholas V. Perricone
-
Patent number: 8642808Abstract: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.Type: GrantFiled: April 22, 2011Date of Patent: February 4, 2014Assignee: ChemoCentryx, Inc.Inventors: Solomon Ungashe, Zheng Wei, John J. Wright, Andrew Pennell, Brett Permack, Thomas Schall
-
Patent number: 8642533Abstract: The present invention relates to methods of maintaining, and methods of restoring, a desired calcium homeostasis in a non-human terrestrial animal by administering an effective amount of one or more Calcium-Sensing Receptor modulators (CaSRs) to the animal. The invention further provides methods of reducing foot lesions in chickens. The invention also relates to food compositions useful in the methods of the invention.Type: GrantFiled: May 22, 2009Date of Patent: February 4, 2014Assignee: MariCal, Inc.Inventors: H. William Harris, Jr., Marlies Betka, Chris Frederick Holm, Steven Harold Jury
-
Publication number: 20140030323Abstract: The present invention provides a controlled-release composition which provides a therapeutically effective plasma concentration of N-acetylcysteine over prolonged period of time. The present invention also includes the use of the controlled-release composition, either alone or in combination with at least one additional active agent, for reduction of vascular inflammation marker and treatment of diseases, conditions, and/or symptoms associated with systemic and/or vascular inflammation in a patient. Furthermore, the present invention provides a process of making granules comprising N-acetylcysteine, or a salt, solvate, prodrug, and/or analog thereof.Type: ApplicationFiled: July 31, 2013Publication date: January 30, 2014Applicant: TIARA PHARMACEUTICALS, INC.Inventors: Yadon ARAD, Liang C. Dong
-
Publication number: 20140030224Abstract: The present invention relates to methods and pharmaceutical compositions for inhibiting influenza virus replication. More particularly, the present invention relates to a compound selected from the group consisting of Gemcitabine, Obatoclax Mesylate, Docetaxel, HA-14, Alsterpaullone, GSK3B inhibitor VIII, GSK3B inhibitor XV, Indirubin 3?- monoxime, L glutathione reduced, Fluocinolone acetonide, Tirofiban, Topotecan hydrochloride, Clofarabine, Vinblastine, Menadione Crystalline and derivatives or analogues thereof for use in the treatment of an influenza infection in a subject in need thereof.Type: ApplicationFiled: April 10, 2012Publication date: January 30, 2014Applicant: UNIVERSITÉ CLAUDE BERNARD - LYON 1Inventors: Vincent Lotteau, Benoit De Chassey, Patrice Andre, Laurene Meyniel-Schicklin, Anne Aublin-Gex
-
Patent number: 8637573Abstract: The invention relates to a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. In addition an effective dose regimen of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g. in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyclic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy.Type: GrantFiled: March 23, 2012Date of Patent: January 28, 2014Assignee: Iasomai ABInventors: Tiziana Parasassi, Maria Grazia Porpora
-
Patent number: 8637572Abstract: Disclosed is a novel composition which has an effect on promoting production of collagen. The composition has high photostability and is free from side effects such as those of retinoids. Specifically disclosed is a composition for promoting collagen production which contains one or more compounds selected from the group consisting of D-aspartic acid, D-alanine, derivatives and/or salts thereof. The composition may be used for the purpose of suppressing and/or improving skin a condition. The skin condition may include but is not limited to photoaging and/or wrinkles. The composition may be used for an external preparation for the skin or food. The composition may be a composition for promoting type I collagen production.Type: GrantFiled: September 27, 2010Date of Patent: January 28, 2014Assignee: Shiseido Company, Ltd.Inventors: Yutaka Ashida, Yosuke Tojo, Shoichiro Shimada, Chieko Mizumoto, Masashi Mita
-
Publication number: 20140024717Abstract: The present invention relates to a process for the preparation of the mono sodium salt of the derivative 3,5-diiodo-O-[3-iodo-4-(sulphooxy)phenyl]-L-tyrosine (T3S) by starting from the corresponding phenolic compound, in the presence of chloro-sulfonic acid and dimethylacetamide as a solvent. The so obtained T3S compound may conveniently be isolated in a pure form as a solid in good yields. The present invention further relates to the process for T3S preparation, wherein the starting reagent is T2 and further comprising the formulation of such compound in tablets. Furthermore, the invention discloses non-radioactive immunoassays based on T3S derivatives.Type: ApplicationFiled: April 5, 2012Publication date: January 23, 2014Applicant: BRACCO IMAGING S.p.A.Inventors: Pier Lucio Anelli, Maria Argese, Luciano Lattuada, Federico Maisano, Sonia Gazzetto, Laura Galimberti, Valeria Boi, Giovanni Rivolta, Livio Cavalieri, Fulvia Vella
-
Publication number: 20140024716Abstract: A composition including S-allyl-L-cysteine as an active ingredient and having an anti-Helicobacter pylori activity or a gastric mucosa protective effect, a composition for preventing, relieving, or treating gastrointestinal disorders, and a method of using the compositions.Type: ApplicationFiled: July 26, 2013Publication date: January 23, 2014Applicant: PHARMAKING CO., LTD.Inventors: Soon Bae KIM, Gwang Soon KIM, Wan Bae KIM, Wie Jong KWAK, Sung Hye BANG
-
Publication number: 20140024683Abstract: The present invention provides, inter alia, methods and pharmaceutical compositions for preventing, treating, or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma and chronic obstructive pulmonary disease.Type: ApplicationFiled: September 24, 2013Publication date: January 23, 2014Inventors: Charles William EMALA, Peter YIM, George GALLOS, Donald LANDRY
-
Publication number: 20140024715Abstract: The present invention provides a method for preventing blood-brain barrier reperfusion injury in a mammalian blood-brain barrier endothelial cell during reperfusion following ischemic stroke comprising administering an effective amount of a ?-glutamyl-D-cysteine antioxidant to the subject and a kit for doing the same.Type: ApplicationFiled: April 23, 2013Publication date: January 23, 2014Applicant: Rosalind Franklin University of Medicine and ScienceInventor: Darryl R. PETERSON
-
Publication number: 20140018423Abstract: The invention relates to an antimicrobial agent where a cysteine compound is covalently bound to a substrate, in particular by binding through an S—S bridge via a spacer molecule to the substrate. The spacer comprises a carbon chain, optionally interrupted by one or more heteroatoms, e.g. O, S, N, P and Si; the chain is optionally substituted with one or more alkyl groups, preferably lower alkyl groups with 1-5 carbon atoms, hydroxyl groups or alkoxy groups. Also, the invention refers to a substrate that is coated with the antimicrobial agent of the invention. The agent has excellent antimicrobial properties and can be used to coat surfaces and substrates of various devices, such as medical devices or devices used in food handling, in order to prevent or inhibit accumulation and/or growth and/or proliferation and/or the viability of microorganisms and/or formation of biofilm.Type: ApplicationFiled: September 11, 2013Publication date: January 16, 2014Applicant: CYTACOAT ABInventors: Anders Wirsen, Birgitta Agerberth, Gudmundur Gudmundsson, Jacob Odeberg, Torbjorn Lindberg
-
Patent number: 8629169Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.Type: GrantFiled: November 15, 2011Date of Patent: January 14, 2014Assignee: Eli Lilly and CompanyInventors: Stephon Cornell Smith, Renhua Li, Charles Howard Mitch, Tatiana Natali Vetman
-
Publication number: 20140011879Abstract: Tools for diagnosis and management of patients suspected of having or having been previously diagnosed with systemic sclerosis are based on the determination one or more of the markers described herein, specifically, the markers having the amino acid sequence of SEQ ID NOS: 1-62 and 66-76 in a sample from the subject. Specific marker ratios and subsets of markers and ratios identify a patient and further subclassify the patient. The information may be used prospectively to study the response of subclassified patients to existing or novel therapeutic strategies.Type: ApplicationFiled: September 27, 2011Publication date: January 9, 2014Applicant: JANSSEN BIOTECH, INC.Inventors: Frederic Baribaud, Bidisha Dasgupta
-
Publication number: 20140010901Abstract: Provided is a novel bleomycin hydrolase production promoter. Provided is a bleomycin hydrolase production promoter, natural moisturizing factor production promoter, and dry skin remedy, comprising as an active ingredient thereof one or a plurality of ingredients selected from the group consisting of chestnut rose extract, angelica root extract, cork tree bark extract, lamium album extract, rosemary extract, benzenesulfonyl GABA and erythritol.Type: ApplicationFiled: March 14, 2012Publication date: January 9, 2014Inventors: Toshihiko Hibino, Shoko Yamada, Hidekazu Fukushima
-
Patent number: 8623919Abstract: A pharmaceutical composition and methods of producing and application of the composition for treating myocardial infarction of a subject are disclosed. The pharmaceutical composition comprises a therapeutically effective amount of at least one synthesized compound selected from the group consisting of SEC, SPC, SBC, SPEC, SAC, SAMC, and SPRC, and a pharmaceutically acceptable carrier.Type: GrantFiled: August 1, 2008Date of Patent: January 7, 2014Assignee: Fudan UniversityInventors: Yizhun Zhu, Qian Wang, Yichun Zhu, Qing Mu
-
Publication number: 20140005268Abstract: Pharmaceutical composition for treating oxidative stress induced pathology, comprising an association of the active ingredients methionine, cysteine and phenylalanine in association with at least one pharmaceutical excipient; said active ingredients being present in a methionine/phenylalanine molar ratio between 2.5 and 12.5; and in a methionine/cysteine molar ratio between 2 and 10.5; and the three active ingredients being present in free state, such as inner salt, or in the form of pharmaceutically acceptable salt; wherein said pharmaceutical composition is used for treating one of the oxidative stress induced pathologies, including intestinal system disorders, such as intestinal wall irritations, hemorrhoids of types 1, 2, 3 and 4 of Goligher classification. It is also disclosed the use of said composition in preparing a medication for treating oxidative stress induced pathology.Type: ApplicationFiled: January 18, 2012Publication date: January 2, 2014Inventor: Eduardo Motta Alves Peixoto
-
Publication number: 20130338165Abstract: Methods of treating Parkinson's Disease comprising administering compounds that up-regulate cystine-glutamate exchange (system Xc?) and/or increase glutathione levels in the brain cells. Preferred compounds are cysteine/cystine prodrugs or N-acetyl cysteine (NAC) prodrugs.Type: ApplicationFiled: June 17, 2013Publication date: December 19, 2013Inventors: David A. Baker, Daniel G. Lawton, Chad Beyer, Michael Neary
-
Publication number: 20130338117Abstract: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided.Type: ApplicationFiled: August 27, 2013Publication date: December 19, 2013Applicant: The Trustees of the University of PennsylvaniaInventor: Robert P. RICCIARDI
-
Patent number: 8609649Abstract: One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-I Trp32, including molecules that bind in a site adjacent to SOD-I Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease.Type: GrantFiled: March 20, 2008Date of Patent: December 17, 2013Assignee: Brandeis UniversityInventors: Jeffrey N. Agar, Gregory A. Petsko, Dagmar Ringe, Walter R. P. Novak
-
Patent number: 8609165Abstract: A dietary supplement can optimize glucose levels, increase energy, and provide other health benefits including combinations of alpha lipoic acid, vanadium, zinc, vitamin C and biotin.Type: GrantFiled: July 2, 2010Date of Patent: December 17, 2013Assignee: E5 LLCInventors: Kevin M. Andrews, Randall P. Wight
-
Publication number: 20130331450Abstract: Disclosed are compositions and methods for treating bacterial infections.Type: ApplicationFiled: March 15, 2013Publication date: December 12, 2013Applicant: Purdue Research FoundationInventors: Cynthia Stauffacher, Mark Alfred Lipton, Mohamed Naguieb Saleem, Tim Jonathan Schmidt, Calvin Nicklaus Steussy, JR., Victor W. Rodwell
-
Publication number: 20130317107Abstract: The described invention provides methods for treating a disease, disorder or condition comprising an inflammatory component that includes a platelet dysfunction component and methods for monitoring therapeutic efficacy of a therapeutic regimen for managing a disease comprising an inflammatory component that includes platelet dysfunction.Type: ApplicationFiled: March 13, 2013Publication date: November 28, 2013Inventors: Leonore A. Herzenberg, Rabin Tirouvanziam, Tetyana Obukhanyck, Yael Gernerz
-
Patent number: 8592482Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.Type: GrantFiled: July 7, 2011Date of Patent: November 26, 2013Assignee: University of Kentucky Research FoundationInventor: Jayakrishna Ambati
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Publication number: 20130303466Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: November 14, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Alain D. Baron
-
Publication number: 20130296328Abstract: The present invention provides new target gene regions for use in prediction, prognosis, diagnosis and therapy of breast cancer, based on the differential methylation profile of said targets in samples from subjects with breast cancer and healthy subjects.Type: ApplicationFiled: January 20, 2012Publication date: November 7, 2013Applicant: Université Libre de BruxellesInventors: François Fuks, Sarah Dedeurwaerder, Christos Sotiriou, Christine Desmedt
-
Publication number: 20130296430Abstract: The described invention provides a method for treating a behavioral deficit, such as irritability and stereotypic/repetitive behaviors, in a subject with autism spectrum disorder by administering a composition comprising a therapeutic amount of N-acetylcysteine, a derivative of N-acetylcysteine, or a pharmaceutically acceptable salt of N-acetylcysteine.Type: ApplicationFiled: March 11, 2013Publication date: November 7, 2013Inventors: Antonio Hardan, Rabin Tirouvanziam, Leonora A. Herzenberg
-
Patent number: 8575217Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.Type: GrantFiled: March 16, 2010Date of Patent: November 5, 2013Assignee: Genmedica Therapeutics SLInventors: Alec Mian, Luc Marti Clauzel, Eric Mayoux, Silvia Garcia-Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte, Julio Cesar Castro Palomino Laria